ProMIS Neurosciences granted Fast Track designation by FDA for PMN310

ProMIS Neurosciences (PMN) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to PMN310, the Company’s lead therapeutic candidate in development for the treatment of Alzheimer’s disease, AD. The ongoing PRECISE-AD Phase 1b trial is evaluating PMN310 in patients with early AD. The study is focused on characterizing safety, tolerability, pharmacokinetics, and disease-relevant biomarkers. ProMIS anticipates reporting interim six-month biomarker and safety data in Q2 ’26 and final results in Q4 ’26.